Akorn Inc. up on FDA approval of eye solution product
Akorn Inc. (Nasdaq: AKRX) got a boost Friday morning after the diagnostics and drug developer reported that the Food and Drug Administration approved over-the-counter use of its eye solution product Ketotifen Fumarate Ophthalmic Solution.
Ketotifen Fumarate Ophthalmic Solution is used to relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander.
Shares of Akorn gained 5.42%, or $0.36, to $7.00 in pre-market trading.
